BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Thursday

BioMarin Pharmaceutical (NASDAQ:BMRN) is anticipated to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.54 per share and revenue of $711.05 million for the quarter. BioMarin Pharmaceutical has set its FY 2025 guidance at 4.200-4.400 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. On average, analysts expect BioMarin Pharmaceutical to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

BioMarin Pharmaceutical Stock Up 1.2 %

NASDAQ:BMRN opened at $65.61 on Thursday. The firm’s 50 day simple moving average is $64.79 and its 200 day simple moving average is $71.10. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. BioMarin Pharmaceutical has a one year low of $60.63 and a one year high of $94.85. The company has a market cap of $12.50 billion, a PE ratio of 39.29, a P/E/G ratio of 0.57 and a beta of 0.28.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. William Blair downgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group dropped their price target on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a research report on Wednesday, October 30th. Wedbush upgraded shares of BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Monday, November 4th. Evercore ISI dropped their price target on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $90.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, December 12th. Seven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.